Ignoring spatial heterogeneity in drivers of SARS-CoV-2 transmission in the US will impede sustained elimination - Susswein, Zachary; Valdano, Eugenio; Brett, Tobias; Rohani, Pejman; Colizza, Vittoria; Bansal, Shweta (medRxiv, 2021)
To dissect the transmission dynamics of SARS-CoV-2 in the United States, we integrate parallel streams of high-resolution data on contact, mobility, seasonality, vaccination and seroprevalence within a metapopulation network. We find the COVID-19 pandemic in the US is characterized by a geographically localized mosaic of transmission along an urban-rural gradient, with many outbreaks sustained by between-county transmission. We detect a dynamic tension between the spatial scale of public health interventions and population susceptibility as pre-pandemic contact is resumed. Further, we identify regions rendered particularly at risk from invasion by variants of concern due to spatial connectivity. These findings emphasize the public health importance of accounting for the hierarchy of spatial scales in transmission and the heterogeneous impacts of mobility on the landscape of contagion risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of General Medical Sciences of the NIH under Award Number R01GM123007.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board, Georgetown UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used comes from accessible data repositories. SARS-CoV-2 data is available from the Centers for Disease Control and Prevention (https://covid.cdc.gov/covid-data-tracker/#county-view, https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/geographic-seroprevalence-surveys.html) and the New York Times (https://github.com/nytimes/covid-19-data). Behavior data is available from Safegraph (https://www.safegraph.com/academics) and the Delphi CTIS (https://delphi.cmu.edu/covidcast/surveys/). All data for the study will be available at https://github.com/bansallab/spatialR